Loading...
|
Please use this identifier to cite or link to this item:
https://nccur.lib.nccu.edu.tw/handle/140.119/52721
|
| Title: | 品牌權益與醫師處方行為之關聯性研究-以高血壓藥物為例-
A study of the relationship between brand equity and physician`s prescription behavior-taking antihypertensive drugs as examples- |
| Authors: | 顏厥慈
Yen, Chueh Tzu |
| Contributors: | 張愛華
Chang, Ai Hwa
顏厥慈
Yen, Chueh Tzu |
| Keywords: | 品牌權益
醫師處方行為
第三代購者行為
台灣西藥市場
Brand Equity
Prescription Behavior
Surrogate-Mediated Shopper
Taiwan Pharmaceutical Market |
| Date: | 2010 |
| Issue Date: | 2012-04-17 09:09:35 (UTC+8) |
| Abstract: | 一個品牌所創造的「品牌權益」及所產生的附加價值是指一個品牌能使顧客了解這個品牌所具有的品牌知識及形象並形成聯想，進而引起顧客對品牌認同與適當回應而轉化為實際的購買行動並發展出緊密的忠誠關係，使其他的競爭者不容易取代。 許多的消費品已經證實「品牌權益」對使用者購買行為的影響，但在專業的產品，尤其是藉由「第三者代購模式」決定選購的產品，如：醫藥產品，卻少有此方面的研究。本研究針對台灣醫藥業市場長年位居領導地位，具有相同治療適應症的兩種用藥作「品牌權益」及代購者購買行為的關聯性分析。以北部地區醫師為調查對象，請醫師以問卷方式評估兩種品牌的「品牌權益」並分析的哪些「品牌權益」的因素會影響處方行為，結果發現：
一、品牌權益中「品牌顯著」、「品牌績效」及「品牌形象」對醫師處方行為有顯著影響。醫師對兩種品牌的「品牌權益」看法有明顯的不同，且會視服務的對象(病患)個別情狀況而選擇使用不同的品牌。
二、「品牌聯想」中產品利益的功能性及經驗性對醫師處方行為有顯著的影響。本研究中兩種產品上市時間相近，但醫師還是認知Diovan品牌為一較新品牌而Norvasc則是一個使用廣泛且安全性高產品。
三、Diovan此品牌「品牌顯著」和醫師服務科別有明顯的交互作用。不同服務科別醫師明顯表現出會考慮病人狀況，不會將處方Diovan都列為首選藥物。
四、Norvasc此品牌「品牌績效」和醫師執業年資有明顯的交互作用。執業年資在5 ~10 年間醫師對Norvasc使用後療效最認同。
五、醫師對單一品牌使用趨勢，在最近六個月主要是受品牌權益中「品牌顯著」影響，而在未來繼續使用此品牌則是依據使用後該品牌的品質、可靠度、優越性等因素才決定是否繼續使用該品牌。亦受產品利益象徵性所影響。
六、醫師對兩種品牌選擇使用哪一種品牌的趨勢，在最近六個月主要是受品牌權益中「品牌顯著」與「品牌形象」構面影響，而在未來六個月除了受「品牌顯著」影響外還受「品牌情感」影響。進一步以量化分析，醫師對 Norvasc使用數量在最近 六個月及未來六個月無顯著差異，但對Diovan在未來六個月的使用數量則有顯著
增加。
A successful brand will lead the consumer to link the brand knowledge and image becoming an associative network memory and drive this memory into consumer’s recognition, and then consumer will transfer the recognition into purchasing action and develop royalty to the brand. This can explain how “Brand Equity” influences consumer behavior and why it can create extra value to minimize competition. Many consumer products have confirmed "Brand Equity" influential power related to the consumers’ purchasing behavior; however, only few studies investigate the professional products, such as: medical products and those will go through "Surrogate-Mediated Shopper” purchasing patterns. Our study selected two prescription products with same therapeutic indications and both maintain leading position among all prescription drugs within pass five years to evaluate the relationship between brand equity and physician`s prescription behavior. Our study findings are as follow：
1.“Brand Salience”、“Brand Performance” and “Brand Image ”give influences of physicians’ prescription behavior. Physician can distinguish both brands and will consider individual patient’s status to prescribe different brand.
2. Functional and experimental value of a brand will influence physician’s prescription behavior. In spite less than one year difference of launching time between “Diovan” and “Norvasc”, physician still recognized “Diovan” as a new product while “Norvasc” was a product had been widely used with good safety profile.
3. Physicians serve at different departments showing significant different “Brand Salience” conception of “Diovan”. Physician will depend on patients’ status to choice different anti-hypertensive drugs and “Diovan” is not always the first choice for all hypertensive patients.
4. Physicians have different service years showing significant divergent perception of “Brand Performance” of “Norvasc”. Physicians’ service periods less than 10 years demonstrate most positive recognition of “Norvasc” clinical therapeutic result.
5. Physicians are according to the quality、reliability and superiority of a brand to decide whether continuously using one drug or not. That means “Brand Judgment” is the key influence factor of physician prescription behavior. In addition, it also affected by symbolic value of the brand.
6. Facing two brands trade-off, physicians will base on "Brand Salience” to make decision in the current six months；however, in the future six months,"Brand Feeling” is another key factor that affect physicians’ behavior。Compare with current six months and future six months regarding of prescription quantity, we can find physician will increase prescription quantity of “Diovan” while will not change prescription quantity of “Norvasc”。 |
| Reference: | 中文參考文獻
1. 賀家光(2002)，醫師處方藥品之關鍵決定因素─以高血壓藥為例，國立台北大學企業管理學系碩士論文
2. 黃郁恬(2002)，品牌權益、品牌聲譽一致性、品牌互補性以及品牌來源國對品牌聯盟成效之影響，國立中央大學企業管理研究所碩士論文
3. 柯雨利(2003)，促銷活動對醫師藥物選擇行為之影響，國立成功大學高階管理碩士在職專班碩士論文
4. 曾光華(2003)，醫師處方藥品之關鍵決定因素─以高血壓藥為例，國立台北大學企業管理學系碩士論文。
5. 謝幸燕(2005)，藥商醫院與醫師的處方決策:醫療制度與組織面之脈絡分析，台灣社會學刊, 2005, May,34 :59-114
6. 王致中(2006)，影響醫師口碑傳播意願之因素的探討-以藥品行銷為例，高雄醫學大學藥學研究所碩士在職專班碩士論文
7. 李月華(2006)，以顧客為基礎的品牌權益之探討，臺北科技大學學報第三十九之一期:103-118
8. 吳培滋(2007)，影響醫學中心醫師開立慢性病連續處方簽之因素探討，長榮大學健康科學學院醫務管理學系碩士論文
9. 樊一平(2007)，藥品行銷組合策略與醫師處方行為之關聯性研究，國立中正大學管理研究所EMBA碩士論文
10. 行政院衛生署(2007)，藥事法
11. 聯合新聞(2008)，經濟學獎克魯曼讚台灣健保要美效法，專欄報告
12. 行政院衛生署(2008)，中華民國97年版公共衛生年報
13. 行政院衛生署中央健康保險局(2008)，全民健康保險申報資料九十六年單方藥品申報金額排行
14. 行政院衛生署(2009)，中華民國98年版公共衛生年報
15. 行政院衛生署(2009)，2009年全民健康保險簡介
16.. 行政院衛生署中央健康保險局(2009)，全民健康保險申報資料九十七單方藥品申報金額排行
17. 行政院衛生署(2009)，藥事法施行細則
18. 行政院衛生署(2009)，醫師法
19. 行政院衛生署(2009)，醫師法施行細則
20. 楊志良(2009)，健保永續經營，行政院衛生署簡報
21. 陳麗敏(2009)，製藥產業的發展現況及趨勢，財團法人生物技術開發中心
22. 陳麗敏(2009)，Pfizer併購Wyeth之動機分析及評論，財團法人生物技術開發中心
23. 行政院衛生署(2010)，2010年全民健康保險簡介
24. 沈茂庭(2010)，全民健保藥品給付政策，行政院衛生署中央健康保險局報告
25. 沈茂庭(2010)，Pricing Policy and Reimbursement Methods in Taiwan，行政院衛生署中央健康保險局報告
26. 朱兆文(2010)，生技/製藥產業併購與聯盟合作趨勢，財團法人生物技術開發中心
27. 羅淑慧 (2010)，全球心血管藥物市場及開發動向，財團法人生物技術開發中心
28. 輝瑞公司官方網站: www. pfizer.com；www.pfizer.com.tw
29. 諾華公司官方網站: www.Novatis.com；www.Novatis.com.tw
英文參考文獻
1. Aaker D.,"Developing Business Strategies", 2001edition
2. Bednarik J.,"Does brand differentiate pharmaceuticals ?" Neuroendocrinology Letter, 2005；Vol. 26(December), 635-652
3. Hollander S., Rassui K., "Shopping with other people’s money: The marketing management implications of surrogate-mediated consumer decision making". J of Marketing, 1999; Vol.63 (April), 102-118
4. ITIS,"Industry insights-Pharmaceutical Industry", Taiwan Industry Outlook, 2008
5. Imshealth, "IMS Health Taiwan Quarterly Summary", 2008
6. Imshealth ,"IMS Top-Line Industry Data: 2007-2009", imshealth global report, 2009
7. Jaakkola E., "Customer participation in medical services: Service providers’ perceptions" Proceedings of AMA servicing conference Reims, 2003：12-14.6 and Proceedings of the EMAC conference, Milan, 2005：24-27.5.
8. Jaakkola E., Renko M., "Critical innovation characteristics influencing the acceptability of a new pharmaceutical product format". Journal of Marketing 2006;1-24
9. Jaakkola E. Halinen A., "Problem solving within professional services: Evidence from the medical field". International Journal of Service Industry Management, 2006;Vol. 17(5),409-429
10. Jaakkola E.," Physicians’ views on the inf luence of patient participation on treatment decisions-an explorative study".Health Serv. Manage Res, 2007; 20:174-182
11. Jaakkola E., "Problem solving with professional services-A study of phyaicians’ prescribing decisions" ISBN 978-951-564-409-1 (nid.) ISSN 0357-4652 (nid.) 659.23, 2007
12. Jaakkola E.,"Purchase decision making in professional services: Organisational or consumer buying behaviour?".Marketing Theory 2007; Vol.7(1):93-108
13. Keller Kevin, "Strategic Brand Management",2008 edition
14. Kolter Philip,"Marketing Management", 2008 edition
15. MM&M,"The Pharma Report 2008"; 2008(May):46-55
16. MM&M,"The Pharma Report 2009"; 2009(May):42-49
17. Novatis, "Novatis Annual report", 2006-08 edition
18. Pfizer,"Pfizer Annual report", 2006-08 edition
19. Roaenthal M., Berndt E.,Donohue J.,et.al., "Promotion of prescription drugs to consumers" N.Engl J Med, 2002; 346:498-505 |
| Description: | 碩士
國立政治大學
企業管理研究所
96932030
99 |
| Source URI: | http://thesis.lib.nccu.edu.tw/record/#G0096932030 |
| Data Type: | thesis |
| Appears in Collections: | [企業管理學系] 學位論文
|
Files in This Item:
| File |
Size | Format | |
|---|
| 203001.pdf | 1892Kb | Adobe PDF2 | 2100 | View/Open |
|
All items in 政大典藏 are protected by copyright, with all rights reserved.
|
